Rsfbio
Rancho Santa Fe Bio, Inc ("RSF Bio") is a clinical-stage, cardiovascular therapeutics platform company, based in San Diego, California. Calcific aortic Valve Stenosis (CAVS) affects 3% of …
About - Rsfbio
RSF Bio is a clinical stage cardiovascular therapeutics platform company based in San Diego, California. Below is a description of our leadership team, scientific advisory board, and board …
Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive ... - BioSpace
2021年6月17日 · Rancho Santa Fe Bio, Inc., a San Diego, California-based clinical-stage cardiovascular platform company, announced that it has entered into an exclusive worldwide …
Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) -- Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular …
治疗钙化性主动脉瓣狭窄不止SAVR和TAVR，RSF Bio联合赛诺菲、 …
2022年11月27日 · RSF Bio，全名为Rancho Santa Fe Bio，是一家创立于2019年的临床阶段心血管药物研发公司，总部位于加利福利亚。 目前，RSF Bio与 赛诺菲、妙佑医疗国际以及美国 …
Rancho Santa Fe Bio - Crunchbase Company Profile & Funding
Rancho Santa Fe Bio is a cardiovascular therapeutics company that develops cardiovascular drugs intended to slow the progression of calcification in patients with aortic valve stenosis.
Ataciguat - Rsfbio
Ataciguat is a novel anthranilic acid derivative that belongs to a structural class of soluble Guanyl cyclase (sGC) activators that can activate the oxidized form of sGC. Ataciguat has undergone …
治疗钙化性主动脉瓣狭窄不止SAVR和TAVR，RSF Bio联合赛诺菲、 …
RSF Bio，全名为Rancho Santa Fe Bio，是一家创立于2019年的临床阶段心血管药物研发公司，总部位于加利福利亚。 目前，RSF Bio与 赛诺菲、妙佑医疗国际以及美国国家推进转化科学中 …
药物研发商Rancho Santa Fe与赛诺菲签订Ataciguat全球独家许可 …
2021年6月17日，药物研发商Rancho Santa Fe Bio, Inc.宣布与赛诺菲签订了全球独家授权协议。 该协议为RSF Bio公司提供了赛诺菲公司对Ataciguat的权利。 有了这项许可，RSF Bio将拥有 …
治疗钙化性主动脉瓣狭窄不止SAVR和TAVR，RSF Bio联合赛诺菲、 …
2022年11月27日 · RSF Bio，全名为Rancho Santa Fe Bio，是一家创立于2019年的临床阶段心血管药物研发公司，总部位于加利福利亚。 目前，RSF Bio与 赛诺菲、妙佑医疗国际以及美国 …
- 某些结果已被删除